VG H&N course intro Florence 2016.pptx

Previous Page

Next Page

Page Background

Study

N Regimens

Median

PFS

Median

Survival

Vermorken

NEJM 2008 220 222

Platin/5-Fluorouracil

versus

Platin/5-FU/cetuximab

3.3 months*

5.6 months* 7.4 months*

10.1 months*

Vermorken

Lancet Oncol

2013

330 327

Cisplatin/5-Fluorouracil

versus

Cisplatin/5-FU/panitumumab

4.6 months*

5.8 months* 9 months

11.1 months

Stage III/IV: curative intention

Recurrent/metastatic: first-line

* Statistically significa